EMA recommendation triggers $40M payment for blood disorder drug

Incyte and Novartis' blood disorder drug ruxolitinib was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use an enlarged spleen therapy in myelofibrosis patients. The recommendation will bring Incyte a $40 million milestone payment from Novartis. The drug is called Jakavi in Europe and Jakafi in the U.S., where it was approved by the FDA in November.

View Full Article in:

Bloomberg Businessweek · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Information Officer
Meridian Health Plan
Detroit, MI
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN